Results 201 to 210 of about 4,863,715 (431)

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies

Experimental Hematology & Oncology
Relapsed/refractory T cell-derived malignancies present with high heterogeneity and poor prognoses. Recently, chimeric antigen receptor (CAR)-T cell therapy has shown remarkable safety and efficacy in the treatment of B cell-derived malignancies. However,
Haiqiong Zheng, Houli Zhao, Shi Han, Delin Kong, Qiqi Zhang, Mingming Zhang, Yijin Chen, Meng Zhang, Yongxian Hu, He Huang   +9 more
doaj   +1 more source

The T cell antigen receptor [PDF]

Biochemical Journal, 1985
M J Owen, M K L Collins
openaire   +3 more sources

Quantitative tracing of mRNAs for T- and B-lymphocyte receptor genes in individual cells by in situ hybridization with fluorochrome-labeled gene probes. I. Expression in malignancies carrying B-lineage associated antigens [PDF]

, 1989
P Mar, Katharina Pachmann, K Reinecke, Bertold Emmerich, E Thiel   +4 more
openalex   +1 more source

Impact of molecular diagnostics and targeted cancer therapy on patient outcomes (MODIFY): a retrospective study of the implementation of precision oncology

Molecular Oncology, EarlyView.
The authors conducted a retrospective study of 94 patients with advanced cancer who underwent next‐generation sequencing (NGS) gene panel analysis and received targeted treatments when applicable. Results further support evidence indicating that molecular profiling provides clinical benefit.
Michaël Dang, Anna Schritz, Nikolai Goncharenko, Guy Berchem   +3 more
wiley   +1 more source

Clonal rearrangement and expression of the T cell receptor beta gene and involvement of the breakpoint cluster region in blast crisis of CGL [PDF]

, 1986
Luen Chow Chan, Andrew J. Furley, AM Ford, DA Yardumian, MF Greaves   +4 more
openalex   +1 more source

Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR

Molecular Oncology, EarlyView.
Analysis of ESR1 mutations in plasma cell‐free DNA (cfDNA) is highly important for the selection of treatment in patients with breast cancer. Using multiplex‐ddPCR and identical blood draws, we investigated whether circulating tumor cells (CTCs) and cfDNA provide similar or complementary information for ESR1 mutations.
Stavroula Smilkou, Aliki Ntzifa, Victoria Tserpeli, Ioanna Balgkouranidou, Alkistis Papatheodoridi, Evangelia Razis, Helena Linardou, Christos Papadimitriou, Amanda Psyrri, Flora Zagouri, Stylianos Kakolyris, Evi Lianidou   +11 more
wiley   +1 more source

Understanding the role of B-cells in CAR T-cell therapy in leukemia through a mathematical model [PDF]

arXiv
Chimeric Antigen Receptor T (CAR-T) cell therapy has been proven to be successful against different leukaemias and lymphomas. This paper makes an analytical and numerical study of a mathematical model describing the competition of CAR-T, leukaemias tumor and B cells.
arxiv  

The Human T-Cell Receptor

Annual Review of Immunology, 1984
Meuer, S, Acuto, O, Hercend, T, Schlossman, S, Reinherz, E   +4 more
openaire   +4 more sources

INDEPENDENT EXPRESSION OF HUMAN T CELL DIFFERENTIATION ANTIGENS AND E ROSETTE RECEPTOR ON PHYTOHEMAGGLUTININ-STIMULATED T LYMPHOCYTES

, 1978
P. A. Dougherty, Edwin W. Ades, Charles M. Balch   +2 more
openalex   +1 more source

Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2 [PDF]

, 1988
Waldmann Ta, C K Goldman, KF Bongiovanni, S O Sharrow, MP Davey, KB Cease, SJ Greenberg, DL Longo   +7 more
openalex   +1 more source